Tootfinder

Moderna and Merck released Phase 3 trial data showing that their personalized
✅ mRNA cancer vaccine,
#intismeran #autogene (mRNA-4157),
combined with the immunotherapy Keytruda,
⭐️cut the risk of melanoma recurrence or death by 42%
⭐️and the risk of cancer spread by 38%.

Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report
Merck and Moderna released detailed results on an experimental vaccine to treat the skin cancer.